describes the methods for the treatment of cardiovascular diseases and related conditions and symptoms (eg, cardiac arrhythmia, vascular disease, myocardial infarction, congestive heart failure, myocarditis, atherosclerosis and \u0440\u0435\u0441\u0442\u0435\u043d\u043e\u0437\u0430), including the introduction in this entity \u0442\u0435\u0440\u0430\u043f\u0435\u0432\u0442\u0438\u0447\u0435\u0441\u043a\u0438 effect for the number of \u044d\u043b\u0435\u043a\u0442\u0440\u043e\u043a\u0438\u043d\u0435\u0442\u0438\u0447\u0435\u0441\u043a\u0438 modified water liquidas described in the text of the application.in some aspects \u044d\u043b\u0435\u043a\u0442\u0440\u043e\u043a\u0438\u043d\u0435\u0442\u0438\u0447\u0435\u0441\u043a\u0438 modified aqueous fluids include aqueous ionic solution \u043a\u0438\u0441\u043b\u043e\u0440\u043e\u0434\u0441\u043e\u0434\u0435\u0440\u0436\u0430\u0449\u0438\u0445 ofnano structures with \u0441\u0442\u0430\u0431\u0438\u043b\u0438\u0437\u0438\u0440\u043e\u0432\u0430\u043d\u043d\u044b\u043c \u0437\u0430\u0440\u044f\u0434\u043e m, which mainly have an average diameter less than about 100 nm, which is sufficient to allow the modulation of at least one potential cellular me \u043c\u0431\u0440\u0430\u043d\u044b and conductivity of the cell membrane.methods and compositions are described for \u044d\u043b\u0435\u043a\u0442\u0440\u043e\u043a\u0438\u043d\u0435\u0442\u0438\u0447\u0435\u0441\u043a\u0438 modified liquids (for example, \u044d\u043b\u0435\u043a\u0442\u0440\u043e\u043a\u0438\u043d\u0435\u0442\u0438\u0447\u0435\u0441\u043a\u0438 modified enriched gas liquids and liquid s) and therapeutic compositions, as well as the use of \u044d\u043b\u0435\u043a\u0442\u0440\u043e\u043a\u0438\u043d\u0435\u0442\u0438\u0447\u0435\u0441\u043a\u0438 modified aqueous liquids in a context, including, but not limited to, oh \u043f\u0435\u0440\u0430\u0446\u0438\u0438 pertaining to the cardiovascular system.furthermore, additional aspects describe ways to measure the b
